An Update on Emerging Therapies for Cystic Fibrosis and Their Implications for Clinical Outcomes

With the rapid progress in the field of cystic fibrosis (CF), healthcare providers are continuously challenged to keep abreast of the latest data in the treatment and management of CF to achieve optimal care of people with CF. This activity provides analyses and clinical perspectives of new and emerging clinical trials data on CFTR modulators presented at the 2018 European Cystic Fibrosis Society (ECFS) Conference*. International expert faculty will examine these latest data, deliberate on the challenges associated with the evaluation of new agents, and discuss the implications of these data for people with CF.

*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.

Target Audience

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with CF.

Educational Objectives 

Upon completion of this activity, participants will be better able to do the following:

  1. Analyze current and emerging CFTR modulator-related trial data as presented at ECFS Conference 2018
  2. Explain the potential mechanism of actions of these various agents
  3. Identify the implications of these data for people with CF
  4. Examine the challenges of early phase evaluation of these novel agents and appropriate study design

Faculty

 
Professor Kevin W. Southern, MBChB, MRCP, FRCPCH, PhD (Chair)
Professor of Child Health
Department of Women’s and Children’s Health
University of Liverpool, Liverpool, United Kingdom
Professor Steven M. Rowe, MD, MSPH
Nancy R. and Eugene C. Gwaltney Family Endowed Chair in Medical Research
Director, CFF Therapeutics Development Network
Director, Gregory Fleming James Cystic Fibrosis Research Center
University of Alabama at Birmingham, United States
Professor Claire Wainwright, MD
Professor of Children’s Health Queensland Clinical Unit and Centre for Child Health Research
University of Queensland, Australia

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Relationship Identified With:

Professor Kevin W. Southern, MBChB, MRCP, FRCPCH, PhD (Chair)
No relationships to disclose
Professor Steven M. Rowe, MD, MSPH
Consultant/Advisor: Bayer and Vertex Pharmaceuticals Inc.
Grants/Research Support: Vertex Pharmaceuticals Inc., Bayer, PTI, Synedgen, Renovion, and Astra Zeneca.
Professor Claire Wainwright, MD
Consultant/Advisor: Funding to institution –  DKBmed LLC, Novartis Pharmaceuticals, The University of Miami, Vertex Pharmaceuticals Inc.
Grants/Research Support: Funding to institution – Ablynx NV, Vertex Pharmaceuticals Inc.

Non-faculty: Lisa G. Sullivan; Shilpa Mudgal; Yulyana; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Vertex Pharmaceuticals Inc..

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and In Vivo Academy Limited

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education (EOCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Elsevier Office of Continuing Medical Education designates program for a maximum of 1.0 AMA PRA Category 1 Credit™.

The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu. Additional information on the process of converting AMA PRA Category 1 Credit™ to ECMECs® can be found at: www.eaccme.eu.

CME Credit (AU Physicians)

Fellows of the Royal Australasian College of Physicians (RACP), i.e. specialists from Australia and New Zealand, can claim participation in this activity as CPD credits in the RACP MyCPD program.

This program has been planned and implemented in accordance with the accreditation requirements and policies of ACCME, and codes and regulations that apply to independent education, including but not limited to ACPE, OIG Compliance Program Guidance for Pharmaceutical Manufacturers and PhRMA code on Interaction with Health Care Professionals.

CE Credit (Nurses)

In support of improving patient care, this activity has been planned and implemented by Dannemiller and the Elsevier Office of Continuing Medical Education. Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Dannemiller designates this educational activity for 1.00 contact hours.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The Elsevier Office of Continuing Medical Education, In Vivo Academy, and Vertex Pharmaceuticals Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Nursing Contact Hours
  • 1.00 Non-physician
Course opens: 
08/13/2018
Course expires: 
08/12/2019
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Nursing Contact Hours
  • 1.00 Non-physician

Accreditation Period

Course opens: 
08/13/2018
Course expires: 
08/12/2019
Please login or register to take this course.